COST-EFFECTIVENESS ANALYSIS OF THE TWENTY-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST THE THIRTEEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR PAEDIATRIC VACCINATIONS IN MOROCCO FROM THE PUBLIC HEALTHCARE PAYER PERSPECTIVE
Author(s)
Dimitra Anglou, MSc.1, Liping Huang, MD2, Hanae Zarrik, PhD3, Sara Derki, PharmD4.
1Pfizer Inc., Tadworth, Surrey, United Kingdom, 2Pfizer Inc., Washington Crossing, PA, USA, 3Pfizer, Casablanca, Morocco, 4Pfizer, Alger, Algeria.
1Pfizer Inc., Tadworth, Surrey, United Kingdom, 2Pfizer Inc., Washington Crossing, PA, USA, 3Pfizer, Casablanca, Morocco, 4Pfizer, Alger, Algeria.
OBJECTIVES: Pneumococcal disease remains a leading cause of morbidity in children in Morocco despite existing vaccination programmes. Current strategies include use of 13-valent pneumococcal conjugate vaccines from Walvax (PCV13-WAL) administered in 3+1 schedule. Following availability of 20-valent pneumococcal conjugate vaccine (PCV20-PFE) in Morocco, this study evaluated the health and economic impact of PCV20-PFE administered in a 2+1 schedule compared with PCV13-WAL 3+1 in the Moroccan paediatric population (0-17 years).
METHODS: A decision-analytic Markov model assessed PCV20-PFE (2+1) versus PCV13-WAL (3+1) in the Moroccan paediatric population from a public healthcare payer perspective over a 10-year horizon, applying annual 3% discounting to costs and health outcomes. Model inputs including disease incidence, serotype distribution, and vaccine effectiveness were sourced from published literature and Moroccan surveillance data where available. Where Moroccan data were unavailable, selected healthcare resource utilization inputs were informed by proxy data from neighbouring countries with similar epidemiology. Direct medical costs were sourced from local hospital data. Outcomes included invasive pneumococcal disease (IPD; meningitis and bacteraemia), hospitalised and non-hospitalised pneumonia, and acute otitis media (AOM) cases and associated deaths and costs. The incremental cost-effectiveness ratio (ICER) was estimated using net costs and QALYs, with deterministic and probabilistic sensitivity analyses conducted to assess results robustness.
RESULTS: Compared with PCV13-WAL 3+1, PCV20-PFE 2+1 was estimated to avert 29,093 additional IPD cases, 462,643 additional hospitalised, non-hospitalised pneumonia and AOM cases, and 7,729 deaths over 10-years, resulting in MAD 18,183 million healthcare cost-savings. Overall, PCV20-PFE was cost-saving versus PCV13-WAL.
CONCLUSIONS: From the Moroccan public payer perspective, PCV20-PFE (2+1) was associated with improved health outcomes and cost savings compared with PCV13-WAL (3+1). Adoption of PCV20-PFE may contribute to reducing pneumococcal disease burden and improving healthcare resource efficiency in the paediatric population.
METHODS: A decision-analytic Markov model assessed PCV20-PFE (2+1) versus PCV13-WAL (3+1) in the Moroccan paediatric population from a public healthcare payer perspective over a 10-year horizon, applying annual 3% discounting to costs and health outcomes. Model inputs including disease incidence, serotype distribution, and vaccine effectiveness were sourced from published literature and Moroccan surveillance data where available. Where Moroccan data were unavailable, selected healthcare resource utilization inputs were informed by proxy data from neighbouring countries with similar epidemiology. Direct medical costs were sourced from local hospital data. Outcomes included invasive pneumococcal disease (IPD; meningitis and bacteraemia), hospitalised and non-hospitalised pneumonia, and acute otitis media (AOM) cases and associated deaths and costs. The incremental cost-effectiveness ratio (ICER) was estimated using net costs and QALYs, with deterministic and probabilistic sensitivity analyses conducted to assess results robustness.
RESULTS: Compared with PCV13-WAL 3+1, PCV20-PFE 2+1 was estimated to avert 29,093 additional IPD cases, 462,643 additional hospitalised, non-hospitalised pneumonia and AOM cases, and 7,729 deaths over 10-years, resulting in MAD 18,183 million healthcare cost-savings. Overall, PCV20-PFE was cost-saving versus PCV13-WAL.
CONCLUSIONS: From the Moroccan public payer perspective, PCV20-PFE (2+1) was associated with improved health outcomes and cost savings compared with PCV13-WAL (3+1). Adoption of PCV20-PFE may contribute to reducing pneumococcal disease burden and improving healthcare resource efficiency in the paediatric population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE440
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Disease
Pediatrics, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines